Asparagine

Asparagine

SCHEMBL1163213

CC(C)[C@H](N)C(=O)O.NC(=O)CC(N)C(=O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.62
SLC1A3 P43003 4/20 0.50
SLC1A2 P43004 4/20 0.50
SLC1A1 P43005 3/20 0.50
GRIK1 P39086 10/20 0.47
GRIK2 Q13002 5/20 0.47
GRM1 Q13255 1/20 0.47
GRM2 Q14416 1/20 0.47
GRIA4 P48058 3/20 0.44
GRIK3 Q13003 3/20 0.44
GRIK5 Q16478 3/20 0.44
GRIA2 P42262 2/20 0.44
GRIA1 P42261 1/20 0.44
ALOX15 P16050 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL8487870 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8712670 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8487875 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8712672 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8892690 0.96 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8892693 0.96 SLC7A5 (0.58) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL18614518 0.93 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL20913225 0.93 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL3443446 0.93 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL27563977 0.93 SLC7A5 (0.64) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464656-A1 NOVEL PEPTIDE AND USE THEREOF Ensoltek Co., Ltd. (KR) 2012-06-20 EP claimed
WO-2011019123-A1 NOVEL PEPTIDE AND USE THEREOF ENSOLTEK CO., LTD. (KR) 2011-02-17 WO claimed
WO-2024112480-A1 TREATMENT REGIMENS AND METHODS OF USING QUERCETIN TO PREVENT AND/OR TREAT MUSCLE WASTING DISORDERS UNIVERSITY OF SOUTH CAROLINA (US) 2024-05-30 WO disclosed
CN-102954773-B Charged particle micro imaging method FEI 公司 2016-12-21 CN disclosed
WO-2012162856-A1 CRYSTAL OF CYTOKINE RECEPTOR NOVO NORDISK A/S (DK) 2012-12-06 WO disclosed
US-20120190625-A1 NOVEL PEPTIDE AND USE THEREOF ENSOLTEK CO., LTD. (KR) 2012-07-26 US disclosed
EP-2464656-A1 NOVEL PEPTIDE AND USE THEREOF Ensoltek Co., Ltd. (KR) 2012-06-20 EP disclosed
WO-2011019123-A1 NOVEL PEPTIDE AND USE THEREOF ENSOLTEK CO., LTD. (KR) 2011-02-17 WO disclosed
US-6794501-B2 Colon cancer antigen panel LUDWIG INSTITUTE FOR CANCER RESEARCH 2004-09-21 US disclosed
US-6784164-B2 ANTIBODY PROTEIN IS EXPRESSED BY STREPTOCOCCUS, CAN BE ELUTED FROM A CHROMATOGRAPHIC COLUMN, USE AS BACTERICIDES, CELL LINE THAT PRODUCES A MONOCLONAL ANTIBODY THE ROCKEFELLER UNIVERSITY 2004-08-31 US disclosed
US-6767719-B1 ISOLATING AND EXPRESSING THESE NUCLEIC ACIDS AND PROTEINS, WHICH HAVE APPLICATION TO THE CONTROL OF CELL PROLIFERATION AND AGING, INCLUDING THE CONTROL OF AGE-RELATED DISEASES, SUCH AS CANCER GERON CORPORATION 2004-07-27 US disclosed
WO-2002046392-A2 X RAY CRYSTAL STRUCTURES AT 5.5 A RESOLUTION OF FUNCTIONAL COMPLEXES OF THE BACTERIAL RIBOSOME CONTAINING TRANSFER RNA AND MODEL MESSENGER RNAS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-06-13 WO disclosed
US-6100071-A ANTAGONISTS FOR ANTIPROLIFERATIVE AGENTS AND ANGIOGENESIS INHIBITORS; COMPOSED OF TYROSINE KINASE RECEPTOR-DERIVED IMMUNOGLOBULIN-LIKE DOMAINS 1, 2, AND 3 FROM THE FLT-1 RECEPTOR AND/OR THE KDR RECEPTOR GENENTECH, INC. (US) 2000-08-08 US disclosed
US-5955345-A DNA SEQUENCES THAT CODE FOR PANCREATIC POLYPEPTIDE; FOR DIAGNOSIS OF AND SCREENING FOR INSULIN-DEPENDENT DIABETES; ANTIDIABETIC AGENTS BAYER CORPORATION FORMERLY MOLECULAR DIAGNOSTICS INC. (US) 1999-09-21 US disclosed
US-5952199-A A PROTEIN THAT CONTAINS AN IMMUNOGLOBULIN-LIKE DOMAIN; ANTIPROLIFERATIVE/ANTITUMOR AGENTS, TREATMENT OF RHEUMATOID ARTHRITIS, PSORIASIS, DIABETIES, GLAUCOMA, MUSCULAR DISORDERS AND IMMUNE REJECTION OF EYE TRANSPLANTS GENENTECH, INC. (US) 1999-09-14 US disclosed
WO-1992001046-A1 LACCASE PRODUCTION BY RECOMBINANT ORGANISMS VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) 1992-01-23 WO disclosed
WO-1991004036-A1 TREPONEMA HYODYSENTERIAE ANTIGENS HAVING A MOLECULAR WEIGHT OF 39kDa AND DNA ENCODING THEREFOR ML TECHNOLOGY VENTURES, L.P. (US) 1991-04-04 WO disclosed
EP-0302103-A4 COLONY STIMULATING FACTORS HAVING REDUCED LEVELS OF CARBOHYDRATE. APPLIED BIOTECHNOLOGY INC (US) 1989-06-21 EP disclosed
EP-0302103-A1 COLONY STIMULATING FACTORS HAVING REDUCED LEVELS OF CARBOHYDRATE GENETICS INSTITUTE, INC. (US) 1989-02-08 EP disclosed
WO-1988005786-A1 COLONY STIMULATING FACTORS HAVING REDUCED LEVELS OF CARBOHYDRATE GENETICS INSTITUTE, INC. (US) 1988-08-11 WO disclosed